The Body Covers: The 35th Annual Meeting of the Infectious Diseases Society of America
A Study to Evaluate the Clinical and Virologic Efficacy of a Crixivan, DDI, and D4T Combination
Dr. Russell Petrak and colleagues at Metro Infectious Disease Colleagues of Hinsdale, Illinois evaluated the efficacy of the combination of daily ddI (400 mg every morning), with D4T 40 mg bid, with Indinavir 800 mg po tid. An interim analysis was reported which involved 27 patients, of whom 22 were adherent to the study protocol. All the patients were nucleoside analog experienced, but all were protease inhibitor naive. The median plasma viral RNA load fell from 33,581 at baseline to undetectable levels for 94% of the participants at 6 months. For the 22 patients who were adherent to the study protocol, the median CD4 count rose from 97 at baseline to 268 at month six. Although some of the non-adherent patients complained of mild side effects including gastrointestinal distress and peripheral neuropathy, none of these symptoms persisted after withdrawal of the drugs. For the majority of participants, the 6 month regimen was well-tolerated and impressive changes in surrogate immune and virologic markers were noted. ddI, D4T and Indinavir appear to be a promising combination regimen for reverse transcriptase experienced patients.
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.